In particular, germline mutations in Patched1 have been found to be responsible for somatic mutations in medulloblastoma, and 50% of medulloblastomas present loss of PTCH1, loss of SUFU, or gain-of-function of SMO [121,122]. This evidence concerns the gene SUFU and medulloblastoma.